ClinicalTrials.gg
CompletedNCT02233777Updated Sep 8, 2014

Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg

An interventional study of Pregabalin capsules 150 mg of Dexa Medica and Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland in Healthy, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-08.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The present study was conducted to find out whether the bioavailability of 150 mg pregabalin capsules produced by Dexa Medica was equivalent to the reference products (Lyrica® capsule 150 mg, Pfizer Manufacturing Deutschland GmbH, Germany).

Read the detailed description

This was a randomized, open label, two-period, two-sequence, crossover study under fasting condition. The participating subjects were required to have an overnight fast and in the next morning were given orally one capsule of the test drug (Pregabalin 150 mg produced by Dexa Medica) or one capsule of the reference drug (Lyrica® 150 mg, Pfizer Manufacturing Deutschland GmbH, Germany).

Blood samples were drawn immediately before taking the drug (control), at 20, 40 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36 hours after drug administration. Seven days after the first drug administration (washout period), the procedure was repeated using the alternate drug. The plasma concentrations of pregabalin were determined by using validated liquid chromatography with tandem mass spectrometry detection (LC-MS/MS) method.

02

Conditions studied

  • Healthy

Keywords

  • Pregabalin
  • Bioequivalence
  • Bioavailability
  • Pharmacokinetic
  • Antiepileptic
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with absence of significant disease or abnormal laboratory values or laboratory evaluation, medical history, or physical examination during the screening and could be considered healthy based on the evaluation
  • Aged 18-55 years inclusive
  • Preferably non-smokers or smoke less than 10 cigarettes per day
  • Able to participate, communicate well with the investigators and willing to provide written to participate in the study
  • within 18 to 25 kg/m2
  • Vital signs (after 10 minutes rest) within the following ranges:

    • Systolic blood pressure: 100-120 mmHg
    • Diastolic blood pressure: 60-80 mmHg
    • Pulse rate: 60-90 bpm

Exclusion criteria

Exclusion Criteria:

  • Personal/family history of allergy or or to pregabalin or allied drugs
  • Pregnant or lactating women (urinary pregnancy test was applied to women subjects at screening and before taking the study drug)
  • Any major illnesses in the past 90 days or ongoing chronic medical illness e.g. congestive cardiac failure (heart failure), hepatitis, hypotensive episodes, hyperglycemia, etc
  • Presence of any clinically significant abnormal values during screening, e.g. significant abnormality of liver function test (, alkaline phosphatase, total >= 1.5 ), renal function test (serum creatinine concentration > 1.4 mg/dL), etc
  • Positive surface antigen (HBsAg), anti-, or anti-
  • Clinically significant (ECG) abnormalities
  • Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery
  • Past history of anaphylaxis or angiodema
  • History of drug or alcohol abuse within 12 months prior to screening for this study
  • Participation in any clinical trial within the past 90 days calculated from the last visit
  • History of any bleeding or coagulative disorders
  • History of seizure, epilepsy, or any kind of neurological disorders
  • History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm
  • A donation or loss of 300 mL (or more) of blood within 3 months before this study's first dosing day
  • Intake of any prescription, non-prescription drug, food supplements, or herbal medicines within 14 days of this study's first dosing day
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Pregabalin capsules 150 mg of Dexa Medica

    Each capsule contains 150 mg pregabalin.

    Drug: Pregabalin capsules 150 mg of Dexa Medica

  • Active comparator
    Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland

    Each capsule contains 150 mg pregabalin.

    Drug: Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland

Interventions

  • Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

    Also known as: Test product: pregabalin capsules 150 mg of Dexa Medica

  • Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

    Also known as: Reference product: Lyrica® 150 mg, produced by Pfizer Manufacturing Deutschland GmbH, Germany

06

What researchers measure

Primary outcomes

  1. AUCt

    Area under plasma concentration time curve from time zero to the last observed quantifiable concentration was determined from plasma concentrations of pregabalin from the test drug and reference drug.

    Time frame: 36 hours

  2. AUCinf

    Area under plasma concentration time curve from time zero to infinity was determined from plasma concentrations of pregabalin from the test drug and reference drug.

    Time frame: 36 hours

  3. Cmax

    The peak plasma concentration of the drug was determined from plasma concentrations of pregabalin from the test drug and reference drug.

    Time frame: 36 hours

  4. Tmax

    The time needed to achieve the peak plasma concentration was determined from plasma concentrations of pregabalin from the test drug and reference drug.

    Time frame: 36 hours

Secondary outcomes

  1. T1/2

    The elimination half life was determined from plasma concentrations of pregabalin from the test drug and reference drug.

    Time frame: 36 hours

07

Study locations

1 site
  • PT Equilab International
    Jakarta, 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2014
First posted
Sep 8, 2014
Start
Jun 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Sep 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02233777
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Sep 8, 2014
Start date
Jun 2014
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Sep 8, 2014

Study contacts

Ratih SI Putri, MD
principal investigator · PT Equilab International

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion